secwatch.observer — SEC 8-K summary
======================================

Issuer:     TransMedics Group, Inc. (TMDX)
CIK:        0001756262
Form:       8-K
Filed at:   2023-11-06T23:59:59+00:00
Accession:  0000950170-23-059424
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TransMedics Q3 revenue $66.4M (+159% YoY); raises FY2023 guidance to $222-230M
------------------------------------------------------------------------------

- Revenue $66.4M, up 159% YoY; includes $2.1M from new aviation business and $1.6M non-recurring charter revenue.
- Net loss widened to $25.4M from $7.4M, driven by $29.2M non-recurring acquisition costs including $27.2M in-process R&D charge.
- Gross margin 61% vs 71% a year ago, impacted by Summit Aviation transition and legacy charter exit costs.
- Cash $427.1M as of Sep 30; full-year 2023 revenue guidance raised to $222-230M from prior $180-190M.
- Summit Aviation acquisition closed, adding aviation service to organ transplant logistics offering.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1756262/000095017023059424/0000950170-23-059424-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1756262/000095017023059424/tmdx-20231106.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-059424

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer